Status: Ongoing, but not recruiting participants.
ClinicalTrials.gov Identifier: NCT02713204
Regeneron Onyx: A randomized, double masked, active controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular AMD.
Condition: Neovascular Age-Related Macular Degeneration
Study Type: Interventional
Duration: 36 weeks
For additional information on this study, please click hereBack to Clinical Research